PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
犬脾脏 II 期血管肉瘤自体树突状细胞治疗成功的前瞻性研究
英文原题：Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma.
查看英文原题
Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
血管肉瘤是一种侵袭性肿瘤，最常发生于某些品种的大型中年犬。脾脏是最常受累的器官。这项前瞻性治疗研究的目的是评估自体单核细胞衍生树突状细胞（DC）疗法在犬脾脏血管肉瘤II期脾切除后的临床效果。共纳入452只诊断为脾脏血管肉瘤并接受脾切除术的犬。其中，42只II期患犬进入DC治疗研究。42只犬总组的中位生存时间为203天。接受完整DC治疗（≥3次疫苗）的组（n=34）中位生存时间为256天，一年生存率为29%，经年龄和体重调整后的风险比为0.30（P=0.010）。我们进一步观察到每次应用后DC产量显著增加，并证明治疗开始时的DC产量与患者生存显著相关。虽然还需要进一步证据，但我们得出结论，自体单核细胞衍生DC疗法是犬脾脏II期血管肉瘤标准治疗方法的可行替代方案。
展开英文摘要原文
Hemangiosarcoma is an aggressive tumour that most frequently occurs in larger, middle-aged dogs of certain breeds. The spleen is the most commonly affected organ. The aim of this prospective therapy study was to evaluate the clinical effect of autologous, monocyte-derived dendritic cell (DC) therapy in canine hemangiosarcoma stage II after splenectomy.
Dogs (n=452) diagnosed with splenic hemangiosarcoma that underwent splenectomy were enrolled. Of these, 42 dogs with stage II entered the DC therapy study. The median survival time for the total group of 42 dogs was 203 days. The median survival for the group (n=34) that received the full DC therapy (≥3 vaccines) was 256 days, with a 29 % one-year survival rate and a hazard ratio of 0. 30, adjusted to age and bodyweight (P=0. 010).
We further observed a significant increase in DC yield after each application and demonstrated that DC yield at the beginning of treatment is significantly related to patient survival. While further evidence is needed, we conclude that autologous, monocyte-derived DC therapy is a viable alternative to standard treatment methods of canine splenic stage II hemangiosarcoma.
论文信息
- 作者
- Spiller V、Vetter M、Dettmer-Richardt C、Grammel T
- 第一作者单位
- PetBioCell GmbH, Schillerstr. 17, Osterode am Harz 37520, Germany.Germany
- 通讯作者单位
- Department of Gynaecology, Martin Luther University Halle-Wittenberg, Ernst-Grube Str. 40, Halle (Saale) 06120, Germany. Electronic address: martina.vetter@uk-halle.de.Germany
- 期刊
- Veterinary journal (London, England : 1997)2024 Aug
- 原文标识
- PubMed 39004264 · DOI 10.1016/j.tvjl.2024.106196